{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:54:58Z","timestamp":1764276898437,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","award":["2013B-05-009"],"award-info":[{"award-number":["2013B-05-009"]}],"id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["NF130064_nl"],"award-info":[{"award-number":["NF130064_nl"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Postgraduate Award (APA)"},{"name":"Australian Government Research Training Program (RTP) Scholarship"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ymgme.2018.02.009","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T12:55:54Z","timestamp":1518785754000},"page":"518-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific Nf1 knockout mouse"],"prefix":"10.1016","volume":"123","author":[{"given":"Matthew A.","family":"Summers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily R.","family":"Vasiljevski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Mikulec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Schindeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.02.009_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0010","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","article-title":"Neurofibromatosis type 1 (NF1): diagnosis and management","volume":"115","author":"Ferner","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1469-8749.2012.04399.x","article-title":"Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence","volume":"55","author":"Lehtonen","year":"2013","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.spen.2006.01.006","article-title":"Cognitive profile of neurofibromatosis type 1","volume":"13","author":"Levine","year":"2006","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0025","doi-asserted-by":"crossref","first-page":"W99","DOI":"10.2214\/AJR.11.7811","article-title":"Musculoskeletal manifestations of neurofibromatosis type 1","volume":"199","author":"Patel","year":"2012","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0030","first-page":"161","article-title":"Skeletal muscle and motor deficits in neurofibromatosis type 1","volume":"15","author":"Summers","year":"2015","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0035","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1212\/01.WNL.0000098881.95854.5F","article-title":"Neurofibromatosis type 1: motor and cognitive function and T2-weighted MRI hyperintensities","volume":"61","author":"Feldmann","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0040","first-page":"145","article-title":"Case-control study of the muscular compartments and osseous strength in neurofibromatosis type 1 using peripheral quantitative computed tomography","volume":"5","author":"Stevenson","year":"2005","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.humov.2011.05.004","article-title":"Lower extremity strength and hopping and jumping ground reaction forces in children with neurofibromatosis type 1","volume":"31","author":"Johnson","year":"2012","journal-title":"Hum. Mov. Sci."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ajmg.a.35729","article-title":"Exercise capacity impairment in individuals with neurofibromatosis type 1","volume":"161a","author":"de Souza","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0055","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/dmcn.12777","article-title":"Muscle weakness in children with neurofibromatosis type 1","volume":"57","author":"Cornett","year":"2015","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/mus.23324","article-title":"Peripheral muscle weakness in RASopathies","volume":"46","author":"Stevenson","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0065","first-page":"15","article-title":"Muscular force is reduced in neurofibromatosis type 1","volume":"9","author":"Souza","year":"2009","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0070","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/hmg\/7.8.1261","article-title":"Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1","volume":"7","author":"Klose","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0075","doi-asserted-by":"crossref","first-page":"9914","DOI":"10.1073\/pnas.88.22.9914","article-title":"Identification and characterization of the neurofibromatosis type 1 protein product","volume":"88","author":"DeClue","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0080","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1101\/gad.8.9.1019","article-title":"Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues","volume":"8","author":"Brannan","year":"1994","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0085","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/aja.1002020309","article-title":"Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues","volume":"202","author":"Gutmann","year":"1995","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0090","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jnr.490370312","article-title":"Modulation of neurofibromatosis type 1 gene expression during in vitro myoblast differentiation","volume":"37","author":"Gutmann","year":"1994","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.cellbi.2005.12.003","article-title":"Active Ras-induced effects on skeletal myoblast differentiation and apoptosis are independent of constitutive PI3-kinase activity","volume":"30","author":"Karasarides","year":"2006","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0100","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/hmg\/ddt515","article-title":"NF1 is a critical regulator of muscle development and metabolism","volume":"23","author":"Sullivan","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11910-010-0154-y","article-title":"Lipid storage myopathy","volume":"11","author":"Liang","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1097-2765(01)00302-1","article-title":"Activated MEK1 binds the nuclear MyoD transcriptional complex to repress transactivation","volume":"8","author":"Perry","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013604","article-title":"Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition","volume":"5","author":"Penna","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0120","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2012.144","article-title":"Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma","volume":"106","author":"Prado","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0125","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00280-006-0323-5","article-title":"Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration","volume":"59","author":"Brown","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2013.11.013","article-title":"Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib)","volume":"59","author":"El-Hoss","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0135","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0140","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/hmg\/ddr149","article-title":"Neurofibromin (Nf1) is required for skeletal muscle development","volume":"20","author":"Kossler","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2212\u2212 and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0150","first-page":"22","article-title":"Different roles of H-ras for regulation of myosin heavy chain promoters in satellite cell-derived muscle cell culture during proliferation and differentiation","volume":"297","author":"Scholz","year":"2009","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0155","series-title":"Expression of Cre Recombinase in the Developing Mouse Limb Bud Driven by a Prxl Enhancer Genesis (New York, N.Y.: 2000)","first-page":"77","volume":"vol. 33","author":"Logan","year":"2002"},{"key":"10.1016\/j.ymgme.2018.02.009_bb0160","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1101\/gad.345505","article-title":"Pax3\/Pax7 mark a novel population of primitive myogenic cells during development","volume":"19","author":"Kassar-Duchossoy","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0165","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.M.00862","article-title":"A combination of rhBMP-2 (recombinant human bone morphogenetic protein-2) and MEK (MAP kinase\/ERK kinase) inhibitor PD0325901 increases bone formation in a murine model of neurofibromatosis type I pseudarthrosis","volume":"96","author":"El-Hoss","year":"2014","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0170","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.semcdb.2008.07.004","article-title":"Bone remodeling during fracture repair: the cellular picture","volume":"19","author":"Schindeler","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0175","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jbmr.528","article-title":"A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells","volume":"27","author":"El-Hoss","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0180","doi-asserted-by":"crossref","first-page":"16474","DOI":"10.1073\/pnas.1307680110","article-title":"Pax7 is critical for the normal function of satellite cells in adult skeletal muscle","volume":"110","author":"von Maltzahn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.ymgme.2018.02.009_bb0185","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/hmg\/ddx423","article-title":"Dietary intervention rescues myopathy associated with neurofibromatosis type 1","volume":"27","author":"Summers","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0190","first-page":"315","article-title":"Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues Cell","volume":"6","author":"Gutmann","year":"1995","journal-title":"Growth Differ."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0195","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1101\/gad.862101","article-title":"Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain","volume":"15","author":"Zhu","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymgme.2018.02.009_bb0200","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218300155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218300155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:22:06Z","timestamp":1761088926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218300155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1096719218300155"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.009","relation":{},"ISSN":["1096-7192"],"issn-type":[{"type":"print","value":"1096-7192"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific Nf1 knockout mouse","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}